Hypertension in chronic kidney disease
CKD-HTN · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Hypertension is both a cause and consequence of CKD and a key driver of progression and cardiovascular death. Management centres on a lower BP target, RAAS blockade for albuminuria, sodium restriction and stepwise add-on therapy.
Red flags
- Accelerated/malignant hypertension with retinal haemorrhages or encephalopathy
- Flash pulmonary oedema suggesting bilateral renal artery stenosis
- Severe hyperkalaemia with ECG changes
- Rapidly worsening renal function on treatment
- BP >180/120 with acute end-organ damage (hypertensive emergency)
Assessment
Differential diagnosis
- Primary hypertension with CKD
- Renovascular hypertension / renal artery stenosis
- Primary hyperaldosteronism
- Volume overload (ESKD/dialysis)
- Glomerular disease with nephrotic-range proteinuria
- White-coat / masked hypertension
Investigations
- Standardised clinic BP plus home or ambulatory BP monitoring
- U&E, eGFR and potassium
- Urine ACR
- Aldosterone:renin ratio if resistant/hypokalaemic
- Renal ultrasound +/- duplex if renovascular disease suspected
- ECG/echo for end-organ damage
Management
- Confirm sustained hypertension with out-of-office readings (home/ABPM) to exclude white-coat effect
- Set target: generally <130/80 mmHg where tolerated, individualised for frailty and orthostasis
- Reinforce sodium restriction (<2 g sodium/day), weight loss, alcohol moderation and exercise
- First-line pharmacotherapy is an ACE inhibitor or ARB, especially with albuminuria; uptitrate to max tolerated
- Recheck U&E/potassium 1-2 weeks after starting or escalating RAAS blockade
- Add a dihydropyridine calcium-channel blocker and/or a thiazide-like diuretic as second/third agents
- Use a loop diuretic instead of thiazide when eGFR <30 mL/min or volume overloaded
- For resistant hypertension confirmed on 3 agents including a diuretic, add spironolactone if potassium and eGFR permit
- Monitor for and manage hyperkalaemia; consider potassium binders to enable RAAS/MRA therapy
- Screen for secondary causes (aldosteronism, renovascular disease) in resistant or hypokalaemic cases
- Assess adherence and remove BP-raising agents (NSAIDs, decongestants)
- Review BP, renal function and potassium at regular intervals and after each change
Drugs & doses
Ramipril 2.5-10 mg PO daily OR losartan 50-100 mg PO daily
Amlodipine 5-10 mg PO once daily
Indapamide 2.5 mg PO once daily (eGFR >30) or furosemide 20-80 mg PO daily (eGFR <30 / overload)
Spironolactone 25 mg PO daily for resistant HTN (if K+ <=4.5, eGFR >45)
Doxazosin MR 4-8 mg PO daily (add-on)
Patiromer 8.4 g PO daily or sodium zirconium cyclosilicate 5-10 g PO daily for hyperkalaemia enabling RAAS therapy
Disposition
Primary care/CKD clinic. Nephrology or hypertension specialist for resistant or secondary hypertension. Emergency assessment for hypertensive emergency/malignant hypertension.
Complications & pitfalls
- Accelerated CKD progression
- Left ventricular hypertrophy and heart failure
- Stroke and cardiovascular events
- Hyperkalaemia from RAAS/MRA therapy
- Hypotension and falls, especially in frail/elderly
- Retinopathy
Exam pearls
- ACE inhibitor/ARB is first-line when albuminuria is present
- Switch thiazide to loop diuretic when eGFR <30
- Confirm resistance with adherence check and out-of-office readings before escalating
- Potassium binders can enable continuation of prognostically important RAAS/MRA therapy
- NSAIDs and decongestants are common hidden causes of resistant hypertension
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.